Omalizumab: a steroid-sparing option for improving pediatric asthma management?
Briars
Leslie A
LA
Department of Pharmacy Practice, College of Pharmacy, The University of Illnois Medical Center at Chicago, 60612, USA. las@uic.edu
Diaz
Anyzeila
A
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D004509:Education, Nursing, Continuing; D006801:Humans; D009722:Nurse Practitioners; D000069444:Omalizumab; D010372:Pediatrics
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab